Journal
CLINICAL LIPIDOLOGY
Volume 4, Issue 3, Pages 279-285Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/CLP.09.12
Keywords
bupropion; Contrave (TM); naltrexone; obesity; weight loss
Categories
Ask authors/readers for more resources
The development of novel pharmacological agents capable of aiding weight loss is urgently required to help combat the global epidemic of obesity. Contrave (TM) is a fixed-dose combination of bupropion sustained release and naltrexone sustained release that is currently being examined in Phase III clinical trials as a potential new pharmacological treatment for obesity. Bupropion, a nonselective dopamine- and norepinephrine-reuptake inhibitor, is believed to reduce weight by stimulating hypothalamic proopiomelanocortin neurons, which in turn act to reduce appetite and increase energy expenditure, a mechanism that is inhibited by beta-endorphin. Naltrexone, a mu-opioid receptor antagonist, acts in a synergistic manner with bupropion to induce weight loss, by blocking the beta-endorphin-mediated inhibition of the proopiomelanocortin neuron. Preliminary results from ongoing Phase III clinical studies have recently reported that Contrave is both safe and efficacious as a pharmacological treatment for obesity, providing a potentially novel therapeutic strategy for its treatment. However, further rigorous clinical testing in nonselected patient populations will be required before this novel treatment strategy enters clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available